Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Clinical Trial Combining TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer

Trial Profile

Phase I/II Clinical Trial Combining TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 04 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Quaratusugene ozeplasmid (Primary) ; Dexamethasone; Dexamethasone; Diphenhydramine; Diphenhydramine; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Genprex
  • Most Recent Events

    • 11 Feb 2022 Status changed from active, no longer recruiting to discontinued.
    • 20 Jul 2020 Planned End Date changed from 1 Jul 2020 to 1 Jun 2021.
    • 09 Jan 2019 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top